We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Pfizer (PFE - Free Report) closed at $52.74, marking a -1.01% move from the previous day. This change lagged the S&P 500's 1.23% gain on the day. At the same time, the Dow added 0.97%, and the tech-heavy Nasdaq gained 0.44%.
Prior to today's trading, shares of the drugmaker had gained 13.51% over the past month. This has outpaced the Medical sector's gain of 4.31% and the S&P 500's gain of 4.69% in that time.
Investors will be hoping for strength from Pfizer as it approaches its next earnings release. The company is expected to report EPS of $1.80, up 93.55% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $28.72 billion, up 96.99% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.20 per share and revenue of $115.85 billion, which would represent changes of +62.9% and +42.17%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Pfizer. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.28% higher. Pfizer is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 7.4. This represents a discount compared to its industry's average Forward P/E of 12.88.
We can also see that PFE currently has a PEG ratio of 0.78. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. PFE's industry had an average PEG ratio of 2.32 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Pfizer (PFE - Free Report) closed at $52.74, marking a -1.01% move from the previous day. This change lagged the S&P 500's 1.23% gain on the day. At the same time, the Dow added 0.97%, and the tech-heavy Nasdaq gained 0.44%.
Prior to today's trading, shares of the drugmaker had gained 13.51% over the past month. This has outpaced the Medical sector's gain of 4.31% and the S&P 500's gain of 4.69% in that time.
Investors will be hoping for strength from Pfizer as it approaches its next earnings release. The company is expected to report EPS of $1.80, up 93.55% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $28.72 billion, up 96.99% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.20 per share and revenue of $115.85 billion, which would represent changes of +62.9% and +42.17%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Pfizer. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.28% higher. Pfizer is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 7.4. This represents a discount compared to its industry's average Forward P/E of 12.88.
We can also see that PFE currently has a PEG ratio of 0.78. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. PFE's industry had an average PEG ratio of 2.32 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 157, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.